Introduction
============

According to the cancer stem cell hypothesis, tumors are composed of a heterogeneous mixture of cells with distinct proliferative and differentiation capacities [@B1]. It is thought that only a small subset of these cells, termed cancer stem cells (CSCs), is able to generate new tumors in recipient animals [@B2]. CSCs possess the capacity of self-renewal, and are responsible for maintaining malignant potential, may acquire migration capacity, and confer resistance to therapy. Several combinations of specific markers and different assays have been used for identifying and isolating CSCs from tumors and tumor cell lines including expression of CD133 and CD44 cell surface markers, the ability to efflux Hoechst 33342 dye, and ALDEFLUOR assay [@B3]. Functional approaches, such as evaluation of the capacity to form non-adherent spheres, are also used. Indeed, most CSCs show the ability to propagate nearly indefinitely *in vitro*without altering their stemness properties [@B4]. This feature allows for *in vitro* enrichment of the isolated initial putative stem population [@B5], [@B6]. Recently, attention has focused on the possible connection between CSCs and the epithelial-mesenchymal-transition (EMT) process. As epithelial cells undergoing EMT, CSCs downregulate epithelial differentiation markers, such as E-cadherin, which are responsible for the loss of cell-cell adhesion capacity, a pivotal change in the progression of many tumors [@B7]. The existence of CSCs in papillary thyroid carcinoma (PTC), the most common endocrine malignancy, was postulated approximately ten years ago [@B8]. However, their presence has been demonstrated only recently [@B9]-[@B12]. The initial lack of information on CSCs in such a common tumor (PTC accounts for approximately 80% of differentiated thyroid carcinoma) [@B13] is possibly due to difficulties in obtaining suitable surgical material and lack of suitable thyroid-specific enrichment markers capable of discriminating stem-like cells within the heterogeneous tumor mass. The PTC-derived cell line B-CPAP [@B14], [@B15] which shares biological features with the primary tumor from which it derives, is one of the few PTC-derived cell lines that is non cross-contaminated with other cell lines [@B16]. Because the genetic profile of B-CPAP is considered representative of most aggressive forms of PTC, it is extensively used for studying PTC carcinogenesis [@B17]-[@B20].

Among features that have been described are genetic alterations, such as*BRAF^V600E^*and *TP53* mutations [@B21], the chromosome profile [@B14] including the molecular karyotype [@B22]-[@B24], a certain degree of chromosome instability [@B25], as well as features of epithelial-mesenchymal transition [@B26]. Nevertheless, functional and molecular studies of putative CSCs have not been extensively reported, as well as the *TERT* promoter status. Here, we further refined the genotype and broadly dissected the functional and molecular profiles and tumorigenic capacity of B-CPAP cell line.

Material and Methods
====================

Cell lines, sphere culture, and functional assays
-------------------------------------------------

The human B-CPAP papillary thyroid carcinoma-derived cell line (kindly provided by Prof. Fusco, the University Federico II, Naples, Italy) was grown as a monolayer in culture in Dulbecco\'s Modified Eagle\'s Medium/Ham\'s F-12 (DMEM/F12) supplemented with 10% fetal bovine serum (FBS, Life Technologies, Milan, Italy), 2mM L-glutamine and 100 UI/ml penicillin and 100 μg/ml streptomycin (Sigma-Aldrich, Milan, Italy), at 37°C in a humidified 5% CO~2~atmosphere.

A sphere-forming assay was used to assess self-renewal and sphere-forming efficiency. For generating thyrospheres, B-CPAP monolayer cells were grown for one week with reduced FBS (5%). Adherent cells were then gently dissociated with StemPro Accutase (Life Technologies), and single cells were cultured in permissive condition, at a density of 2x10^4^ cells/ml in low-attachment flasks (Corning, Corning, NY, USA), in serum-free medium (SFM) as follows: DMEM/F12 with 2% B27 supplement (Life Technologies) and epidermal growth factor (EGF), and basic fibroblastic growth factor (bFGF) (Miltenyi Biotec, Calderara di Reno, BO, Italy) (20 ng/ml each). Monitoring of thyrosphere formation was done with an Olympus IMT-2 inverted microscope (San Diego, CA, USA); images were captured with a Moticam Pro digital camera (Motic, Seneco, MI, Italy).

To confirm self-renewal, primary thyrospheres of approximately 200 μm in size were enzymatically dissociated with StemPro Accutase (Life Technologies) and replated in SFM every seven days at a density of 2x10^4^cells/ml to obtain next generation spheres.

To evaluate sphere forming efficiency (SFE), thyrospheres were dissociated and seeded at a cell density of 500 cells/ml in low-attachment 24-well plates (Corning) in SFM. Every 15 days, spheres that had formed were counted, dissociated, and replated to generate new spheres. The numbers of spheres counted were expressed as a percent of total plated cells.

To induce differentiation of thyrospheres into adherent cells, thyrospheres were cultured in medium supplemented with 10% FBS for at least 4 weeks, and then harvested for molecular analysis.

Functional parameters and stemness markers of B-CPAP thyrospheres were compared to thyrospheres isolated (see above) from a normal thyrocytes-derived cell line. Nthy-ori 3-1 (SV-40 immortalized normal human thyroid follicular cells) was purchased from Health Protection Agency Culture Collections. Expression of B-CPAP differentiation markers were in preference compared to normal thyroid tissue.

Reverse Transcription Polymerase Chain Reaction
-----------------------------------------------

Total RNA was extracted from multiple populations including parental cells, various thyrosphere generations, and sphere-derived adherent cells. TRI Reagent Isolation Solution (Sigma-Aldrich) was used according to the manufacturer\'s instructions, and concentration, integrity, and purity were determined by NanoPhotometer^TM^P300 Version 1.0 (Implen GmbH, München, Germany) for each cell subset.

RNA (1 μg) was reverse transcribed into cDNA using Oligo (dT) 12-18 primers (Life Technologies) and Moloney Murine Leukemia Virus reverse transcriptase (M-MLV; 200 U; Life Technologies) according to the manufacturer\'s instructions. cDNA was subsequently amplified by polymerase chain reaction (PCR) according to Lan [@B27]. Primers and reaction conditions are summarized in Table [S1](#SM1){ref-type="supplementary-material"}. PCR products were separated by 2% agarose gel electrophoresis, stained with SYBR Safe (Life Technologies), and visualized with a UV transilluminator (ECX-F20M, CSL-MicroDOC-Compact Gel documentation system, Eppendorf, Hamburg, Germany). Signals corresponding to each gene were analyzed using Quantity One software (Bio-Rad Hercules, CA, USA). mRNA amounts were normalized by comparison to GAPDH mRNA levels.

Immunofluorescence staining
---------------------------

For immunostaining, cells from dissociated thyrospheres were replated in SFM on poly-D-lysine coated coverslips for 2 hours before fixation. Cells were fixed with cold methanol for 4 minutes at -20°C for all antibodies, except that cells to be stained for ABCG2 were fixed in 4% paraformaldehyde for 10 minutes at room temperature. Immunostaining was performed as previously described [@B28] using antibodies listed in Table [S2](#SM1){ref-type="supplementary-material"}. Alexa-conjugated (Alexa Fluor 488 or 594, Life Technologies) goat anti-mouse or anti-rabbit IgG were used as secondary antibodies. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI).

Western Blot analysis
---------------------

Cells were lysed with 2% sodium dodecyl sulfate at 4°C. Protein concentration was measured according to the method of Lowry [@B29]. Western blot was carried out as previously described [@B28] using antibodies listed in Table [S2](#SM1){ref-type="supplementary-material"}. Horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG (both from DAKO, Carpinteria, CA, USA) were used as secondary antibodies.

Gene Mutation assay
-------------------

Genomic DNA was isolated from both adherent cells and primary thyrospheres using a QIAmp DNA Mini Kit (Qiagen, Milan, Italy). Quantification of genomic DNA was determined by NanoPhotometer (Implen).

### BRAF^V600E^ mutation

Exon 15 of the *BRAF* gene was amplified by PCR as previously described [@B30]. Confirmation of mutation was performed by direct sequencing with an ABI 310 Genetic Analyzer (Applied Biosystems, Milan, Italy) utilizing BigDye ver. 1.1 terminator kit (Applied Biosystems) and specific amplification primers for exon 15 (Life Technologies).

### TP53 mutation

Exons 7, 8, and 9 of *TP53*were analyzed using primers as previously described [@B21]. PCR products were amplified with High-Fidelity Taq polymerase (Platinum® Taq DNA Polymerase High Fidelity, Invitrogen), purified (by exonuclease 1 and shrimp alkaline phosphatase) and sequenced by fluorescence-based Sanger\'s direct sequencing on an ABI 3130 XL DNA capillary sequencer (Applied Biosystems).

### TERT promoter mutation

Standard PCR was carried out for genetic sequencing to identify *TERT* mutation. Briefly, a fragment of *TERT* promoter was amplified by PCR on genomic DNA using primers previously described [@B31]. Thirty nanograms of genomic DNA was used in PCR (initial activation step at 95°C for 3 min, forty cycles of 95°C denaturation for 30 sec, 62°C annealing for 1 min, 72°C elongation for 2,5 min, and a final elongation step at 72°C for 7 min). *TERT* promoter sequences were generated by direct sequencing with an ABI 310 Genetic Analyzer (Applied Biosystems) utilizing BigDye ver. 1.1 terminator kit (Applied Biosystems).

*In vivo* tumorigenicity assay
------------------------------

All the experiments involving animals were carried out in accordance with national and European Guidelines for use and care of laboratory animals, according to a protocol approved by the Italian Ministry of Health (268/2012-B). Four to six week-old female Hsd:Athymic Nude-Foxn1^nu^ mice were obtained from Envigo Italy and maintained under specific pathogen-free conditions before xenograft injection. Viability of B-CPAP thyrospheres or adherent cells was evaluated using trypan blue dye exclusion assay before being resuspended in 50% phosphate buffered saline (PBS)-50% Cultrex (Trevigen, Inc., Gaithersburg, MD, USA) solution. The cell suspension (200 μl) was injected subcutaneously into flanks of Hsd:Athymic Nude-Foxn1^nu^ mice (see results). Tumor growth was measured with a caliper once a week for 7 weeks starting from 7 days post injection. Tumor volume was then calculated according to the following formula: V (mm^3^) = (width^2^ × length)/2. At the end of the experiment, mice were euthanized under anesthesia and tumors were collected for histological and immunohistochemical analyses. Tumorigenicity efficiency was calculated as percentage of number of tumor formation/total of injection sites.

Histopathology and Immunohistochemistry
---------------------------------------

Specimens from tumors were fixed in 10% neutral formalin for 24 hours, and then paraffin embedded. Sections (2 μm) were stained with Hematoxylin & Eosin for morphological evaluation. Specific PTC nuclear features were scanned including clearing, overlapping, grooves, and pseudoinclusions. The architectural pattern (follicular, papillary, solid, sarcomatoid) was evaluated; areas of necrosis and the mitotic index were recorded. Immunohistochemistry (IHC) was performed after heat-mediated antigen retrieval on a Dako autostainer (Glostrup, Denmark) using specific antibodies listed in Table [S2](#SM1){ref-type="supplementary-material"}.

Statistical analysis
--------------------

Results were analyzed using the 2-tailed Student t-test; *P*\<0.05 was considered statistically significant. Statistical analysis was carried out with Prism, 5.00 software (GraphPad Software, Inc, La Jolla, CA).

Results
=======

Functional characterization
---------------------------

### Primary thyrosphere formation

A subpopulation of adherent B-CPAP parental cells was able to form thyrospheres in SFM. Specifically, cells growing in suspension formed three-dimensional aggregates - spheroid clusters - at day 3. Spheres were visible after five days and reached the maximum size of 150-300 μm after seven days (Figure [1](#F1){ref-type="fig"}A). The same behavior was observed for Nthy ori 3-1-derived spheres.

### Self-renewal

To assess the presence of a self-renewing population of stem-like cells within thyrospheres, primary thyrospheres were enzymatically dissociated and re-seeded at the initial cell density. These cells were found to form secondary spheres. B-CPAP cells had an extensive capacity for self-renewal, reaching at least 21 generations (Figure [1](#F1){ref-type="fig"}B). The Nthy ori 3-1 self-renewal capacity was instead limited to four generations (Supplement Figure [1](#F1){ref-type="fig"}A).

### Sphere-Forming Efficiency (SFE)

B-CPAP adherent cells had an initial SFE of approximately 2%. This value increased with each iteration, reaching a peak value at generation 8 (18%±2.1). Although SFE decreased after generation 8, cells maintained a stable efficiency of 10% through the end of the experiment (20^th^generation) (Figure [1](#F1){ref-type="fig"}C). The Nthy ori 3-1 thyrosphere SFE was initially high. However, it diminished from the second sphere generation, by which cells start to flat adhering to the flask surface and gaining epithelial-like morphology in not permissive medium (Supplement Figure [1](#F1){ref-type="fig"}B).

### Thyrosphere differentiation

When B-CPAP thyrospheres were cultured in permissive condition, cells from the outermost layer began flattening and attached to the flask surface usually within 24 h after seeding. By 72 h they had acquired an epithelial-like morphology and were indistinguishable from the adherent parental cells (Figure [1](#F1){ref-type="fig"}D). We refer to these cells as adherent sphere-derived cells.

Molecular characterization
--------------------------

The B-CPAP molecular profiles are summarized in Table [1](#T1){ref-type="table"} and are as follows.

### Reverse Transcription-PCR (RT-PCR)

The expression of stem cell markers (Oct4, Nanog, ABCG2, p63, and ALDH1-A1) and thyroid differentiation markers (Tg, PAX8, and TTF-1) were evaluated by RT-PCR, and were compared among parental adherent cells, thyrospheres, and adherent sphere-derived cells to determine the effect of SFM on expression of stemness/differentiation genes.

Oct4, Nanog, ABCG2, and p63 mRNAs were expressed at comparable levels in all cell subsets; ALDH1-A1 mRNA was expressed in thyrospheres, although it was significantly reduced in adherent parental (p=0.0020) and sphere-derived (p=0.0016) cells (Figure [2](#F2){ref-type="fig"}A).

Thyroglobulin (Tg) expression was negative; PAX8 was equally expressed in all subsets, and TTF-1 exhibited lower expression in thyrospheres compared to adherent parental cells (p=0.0109) and adherent sphere-derived cells (p=0.0056) (Figure [2](#F2){ref-type="fig"}B).

No significant difference in mRNA expression through thyrosphere generations was observed; therefore, immunofluorescence and Western-blot analyses were performed on first generation thyrospheres.

All stemness markers but p63 and ALDH1-A1 were expressed in Nthy ori 3-1 thyrospheres, confirming that ALDH1-A1 was specific of B-CPAP thyrospheres (Supplement Figure [2](#F2){ref-type="fig"}A).

Normal thyroid tissue expressed TTF1, PAX8 and Tg (Supplement Figure [2](#F2){ref-type="fig"}B).

### Immunofluorescence

Thyrospheres were positive for the stem cell marker ALDH1-A1, whereas, TTF-1 differentiation marker was not detectable. In contrast, both adherent parental and adherent sphere-derived cells were clearly labeled for TTF-1, although neither showed immunoreactivity for ALDH1-A1. The other tested stem-related markers CD44, ABCG2, and Oct4 were expressed by all cell populations. The expression of two EMT markers, E-cadherin and vimentin, was evaluated in the different cell populations. All analyzed cell subsets were negative for E-cadherin but were positive for vimentin expression, which was more pronounced in thyrospheres (Figures [3](#F3){ref-type="fig"}A-F).

### Western Blot

Immunoblot analysis confirmed results obtained by RT-PCR and immunofluorescence. ALDH1-A1 protein was expressed exclusively in thyrospheres, whereas, CD44 was present in all cell subsets, although higher expression was observed in thyrospheres compared to adherent parental (p=0.007) and adherent sphere-derived (p=0.0246) cells. p63 was expressed in all cell subsets. In particular, we observed only a 70 kDa band, corresponding to the ΔNp63alpha isoform (Figure [4](#F4){ref-type="fig"}A). TTF-1 transcription factor and the differentiation marker CK19 were detected only in adherent parental and adherent sphere-derived cells, thyroglobulin was absent in all cell populations, whereas normal thyroid tissue expressed TTF1, CK19 and Tg (Figure [4](#F4){ref-type="fig"}B).

Moreover, all B-CPAP cell populations were negative for E-cadherin. Vimentin expression was higher in thyrospheres compared to adherent cell populations although the difference was not statistically significant (Figure [4](#F4){ref-type="fig"}C).

*TERT promoter, BRAF, and TP53 mutations.*Both B-CPAP adherent cells and thyrospheres bore *TERT* C228T, *BRAF^V600E^*, and *TP53* mutations.

Tumorigenicity
--------------

The ability of B-CPAP thyrospheres to induce tumor formation in immunocompromised mice was compared to that of the corresponding adherent cells. Thyrosphere cells were more efficient in inducing tumors when subcutaneously xenografted in Hsd:Athymic Nude-Foxn1^nu^ mice as compared to adherent cells. When thyrosphere cells and adherent cells were inoculated at the same concentration (5x10^5^ cells in 200 μl of volume injection) tumor formation was observed in 4 of 6 (66.67%) mice compared to 3 of 8 (37.50%) mice, respectively. Adherent cells remained less efficient (3 tumors out of 8 injections) when they were inoculated at increased concentration (2x10^6^ cells in 200μl of volume injection) (Figure [5](#F5){ref-type="fig"}A and B), suggesting that B-CPAP thyrospheres were more prone to establish tumors *in vivo* as compared to B-CPAP parental cells. No significant differences in volume were found between adherent cell-derived and thyrosphere cell-derived tumors over seven weeks.

Morphological analysis of tumor masses of tumors derived from B-CPAP adherent parental cells did not exhibit classic PTC-like nuclear features. Tumors were composed of clusters of cells arranged in solid areas, without specific architectural patterns such as follicular or papillary structures. Necrosis was present. A high power field (HPF) evidenced nuclei with severe atypia, hyperchromasia, nuclear membrane irregularities, and pleomorphism. Frequent mitoses were easily found (2-3x10 HPF). Tumors derived from thyrospheres showed similar features, being composed of solid neoplasms with clear-cut malignant features such as angioinvasion. Coagulative necrosis and focal sarcomatoid-storiform areas were evident. IHC analysis indicated the absence of well-differentiated thyroid tumors markers like TTF-1 and Thyroglobulin. Moreover, CK19, HBME1, and p63 (anti-p-40) were negative. Focal reactivity for Galectin-3 was observed, and tumors exhibited a high proliferative index (Mib-1 30-40%) (Figure [5](#F5){ref-type="fig"}C).

Discussion
==========

Despite the recognition that CSCs are present in differentiated primary thyroid tumors [@B9]-[@B11] the contributions of CSCs to generating PTC are poorly investigated. Among the various possible experimental models, human cancer cell lines are frequently used. However, few non cross-contaminated PTC-derived cell lines are available for *in vitro* studies [@B16], and those that exist are not fully characterized. Considering this, we widened the characterization of B-CPAP, one of the most used PTC-derived cell lines, by refining the genetic profile, defining functional aspects and identifying specific biomarkers that allow discrimination between isolated sphere-forming cells (thyrospheres) and parental adherent cells. Moreover, we compared tumorigenicity of the two populations. We isolated cells with thyrosphere-forming capacity from adherent parental cells, and demonstrated that B-CPAP cells have a higher proliferative potential, culminating in the acquisition of putative indefinite self-renewal capacity, then normal thyrocytes. This difference is in agreement with recent data comparing functional aspects of thyrospheres from normal and tumor thyroid tissue [@B32], [@B33]. In our hands, stimulation with EGF and bFGF molecules for several generations was indeed needed for B-CPAP to reach maximal self-renewal capacity, sustaining long-term proliferation and stable growth. Mutated *TP53*, which characterizes B-CPAP cells, might favor this behavior. Cicalese and coworkers [@B34] have demonstrated that unperturbed levels of p53 impose asymmetrical division in mammary stem cells, whereas, loss of p53 favors symmetrical division. Moreover, a potential role of the mutated form of p53 on the deregulation of the self-renewal/differentiation program of CSCs has been suggested [@B35]. In addition, although p63 was equally expressed in adherent and thyrosphere cells, we observed that B-CPAP cells showed only the ΔNp63alpha isoform. ΔNp63alpha is the main isoform in epithelial tissues and is essential for the self-renewal of adult stratified epithelial [@B36] and glandular structures [@B37]. As the expression of p63 in thyroid tumors is controversial, the finding of this specific isoform in B-CPAP cells reinforces the idea that ΔNp63alpha might regulate self-renewal of B-CPAP thyrospheres, and possibly has a role in thyroid carcinoma proliferation in general. Recent data on ΔNp63alpha expression in mammary CSCs indicate that ΔNp63alpha promotes self-renewal and expansion [@B38]. Intriguingly, p63 expression has been detected in thyroid solid cell nests, which may represent a pool of stem cells of the adult thyroid [@B39].

We hypothesize that *TP53* mutation and ΔNp63alpha expression might contribute to promoting B-CPAP self-renewal. Among the other tested stemness-related markers, the expression of ALDH1-A1 distinguished putative CSCs from adherent parental cells. ALDH1-A1 is a major ALDH family enzyme involved in the oxidation of retinol to retinoic acid in early stem cell differentiation [@B40]. Recently, its role as a CSC marker has been reported, as well as its association with poor prognosis in many cancers including lung [@B41], breast [@B42], prostate [@B43], thyroid [@B9], [@B44], head and neck [@B45], and renal [@B46] cancers. According to our results, papillary thyroid carcinoma can be added to this list. Indeed, this feature was also confirmed by the loss of ALDH1-A1 expression in cells derived from thyrospheres grown under differentiation conditions. Based on these observations, we investigated *TERT* promoter mutation in both B-CPAP populations and demonstrated *TERT*C228T mutation. *TERT* mutation represents a new oncogene in approximately 30% of thyroid cancer [@B47]. The mutation induces monoallelic activation of the gene [@B48] and prevents silencing of TERT upon differentiation of stem cells [@B49]. In addition, B-CPAP thyrospheres and parental cells harbored *BRAF^V600E^* mutation. In line with the aggressiveness of the primary tumor from which B-CPAP has been derived, a synergistic effect of *TERT* promoter mutation in combination with *BRAF^V600E^* on poor clinicopathologic outcomes of PTC has been recently proposed [@B50]. Accordingly, we also observed higher expression of CD44 stem marker in thyrospheres than parental cells, lack of expression of TTF-1 and CK19 differentiation markers, downregulation of E-cadherin epithelial marker, and upregulation of vimentin mesenchymal marker. In aggregate, these findings suggested that sphere-forming cells had tumorigenic potential, which was confirmed *in vivo* using immunocompromised mice. Intriguingly, it has been reported that parental B-CPAP cells establish heterotopic tumors in immunocompromised mice (15) at concentrations 6 fold and 1,5 fold higher than the ones we used for testing tumorigenicity of B-CPAP thyrospheres and parental cells, respectively. This suggests that our thyrospheres were enriched for tumor-initiating cells by at least 4 folds compared to parental cells. The IHC analysis of tumor masses confirmed a high proliferation index and absence of classic PTC-markers such as CK19, TTF-1, and HBME1. Lack of these markers is a feature of CSC-rich anaplastic thyroid carcinoma [@B51], and it is also in line with enrichment of stem-like cancer cells in thyrospheres. As a whole, the profile of this cell line is consistent with that of cancer stem-like cell populations observed in aggressive papillary thyroid carcinoma [@B32], [@B33], [@B52].

Conclusions
===========

The B-CPAP cell line, characterized by *TERT* promoter mutation,*BRAF^V600E^*, and *TP53* mutations, possess a subpopulation of cells with cancer stem-like properties and is capable of forming thyrospheres. Thyrosphere cells have a putative indefinite self-renewal capacity. Compared to adherent cells they are characterized by differential expression of two stemness markers (ALDH1-A1 and CD44) and two differentiation markers (TTF-1 and CK19) and have higher tumorigenic potential. The characterization of sphere-forming cells from the B-CPAP cell line reported here may contribute to the development of a useful *in vitro*model for dissecting the origin and progression of papillary thyroid carcinoma.
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![**A**) B-CPAP thyrosphere morphology during growth in SFM. Morphology at 3, 5, 7 days. **B**) Self-renewal assay illustrating propagation of B-CPAP-derived thyrospheres. The graph shows the total number of cells (Y axis) for each generation after 7 days of culture in SFM (X axis).**C**) Sphere Forming Efficiency showing the maintenance of a stable capacity to generate spheres after generation 10. Data represent the means ± SD of three independent experiments. **D**) Thyrosphere in differentiation medium showing a trend toward attaching to the flask at day 2, and toward acquiring an epithelial-like morphology identical to adherent parental cells at day 3.](jcav08p1629g001){#F1}

![**A**) Expression levels of Oct-4, Nanog, ABCG2 and ALDH1-A1 mRNA in B-CPAP.**B**) Expression levels of Tg, PAX8, and TTF-1 mRNA in B-CPAP. Data represent the means ± SD of three independent experiments.](jcav08p1629g002){#F2}

![Immunofluorescence pattern in B-CPAP. **A**) ALDH1-A1 (green) positive thyrospheres and negative adherent cells**B**) CD44 (green) positive cells in all analyzed subsets, with thyrosphere cells showing brighter immunostaining. **C**) ABCG2 (red) expression in analyzed subsets. **D**) Oct4 (red) expression in analyzed cell subsets. **E**) TTF-1 (red) expression in analyzed subsets. **F)** Vimentin (positive, green)/E-cadherin(negative) double staining in analyzed cell subsets. Nuclei are stained with DAPI (blue). Scale bar: 20 µm. Images are representative of three independent experiments. Adherent parental cells: adhP; Sphere-Derived cells: adhSD; thyrospheres: thyS. \* p\<0.05; \*\*p\<0.01.](jcav08p1629g003){#F3}

![B-CPAP Western blot analysis **A**) ALDH1-A1, CD44, and ΔNP63alpha expression in adherent parental cells, adherent Sphere-Derived cells, and thyrospheres (left). Histogram showing expression relative to GAPDH (right). (Data represent the means ± SD of three independent experiments). **B)** Expression of Tg, TTF-1 and CK19. **C**) Expression of E-cadherin and vimentin. Controls: fetal liver (ALDH1-A1 and CD44), fetal brain (ΔNp63alpha); normal thyroid (Tg, CK19, TTF-1, E-cadherin and GAPDH). Adherent parental cells: adhP; adherent Sphere-Derived cells: adhSD; thyrospheres: thyS. \* p\<0.05; \*\*p\<0.01.](jcav08p1629g004){#F4}

![**A**) Representative images of xenografted B-CPAP grown as adherent cells (upper images) or as thyrosphere (lower images). **B**) Percentages of tumor masses after 49 days subcutaneous injection of adherent (adhP) or thyrosphere (thyS) B-CPAP cells. **C**) Representative pictures of tumors from xenografted B-CPAP grown as adherent cells (upper Hematoxylin-Eosin stained images) or as thyrosphere (lower H&E stained images). Morphological analysis of tumors from adherent cells revealed a high-grade thyroid carcinoma with spread coagulative necrosis (upper left, H&E 20X). Frequent mitoses were present (black circle, 40X). Histology in thyrospheres showed diagnostic features of anaplastic-like carcinoma, too. Angioinvasion was evident (inner left, H&E, 20X). Tumor architecture was solid and sarcomatoid (H&E 20X). Immunohistochemical staining for Mib1 confirmed a high proliferative index (around 30%; 20X), TTF-1 (20X), and squamous marker p63 were negative (20X; positive internal control in mouse skin).](jcav08p1629g005){#F5}

###### 

Molecular profile of B-CPAP cell subsets

                                       adhP   thyS    adhSD
  ------------------------------------ ------ ------- -------
  Stemness markers                                    
  *Oct4*                               Pos    pos     pos
  *Nanog*                              Pos    pos     pos
  *ABCG2*                              Pos    pos     pos
  *ALDH1-A1*                           Neg    pos     neg
  *CD44*                               Pos    pos\*   pos
  *p63*                                Pos    pos     pos
  Differentiation markers                             
  *TG*                                 Neg    neg     neg
  *TTF-1*                              Pos    neg     pos
  *PAX8*                               Pos    pos     pos
  *CK19*                               Pos    neg     pos
  EMT markers                                         
  *E-cadh*                             Neg    neg     neg
  *Vimen*                              Pos    pos     pos
  Specific thyroid somatic mutations                  
  *BRAF^V600E^*                        Pos    pos     Pos
  *p53*                                Pos    pos     Pos
  *TERT*                               Pos    pos     Pos

adhP: adherent parental cells (monolayer culture); adhSD: adherent Spheres-Derived cells; EMT: epithelial mesenchymal transition; thyS: thyrospheres. \*Significantly higher expression compared to adhP and adhSD (p=0.007 and p=0.0246, respectively).
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